It was announced on Friday that the European Medicines Agency (EMA) has said that it has recommended revoking the marketing authorisation for a drug manufactured by Swiss-American pharmaceutical firm Novartis, Economic Times has reported.

The drug, Adakveo, had been developed against sickle cell disease.

A review by EMA's human medicines committee (CHMP) said that the drug could come with significant health risks.

The review concluded that the drug could cause severe and serious treatment-related side effects.